We are live on ! Find out more
FUSN

Fusion Pharmaceuticals Inc. Common Shares
FUSN

Delisted

FUSN was delisted on the 3rd of June, 2024.

Back to rankings

51 hedge funds and large institutions have $483M invested in Fusion Pharmaceuticals Inc. Common Shares in 2020 Q2 according to their latest regulatory filings, with 51 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
51
Holders Change
+51
Holders Change %
–
% of All Funds
1.05%
Holding in Top 10
2
Holding in Top 10 Change
+2
Holding in Top 10 Change %
% of All Funds
0.04%
New
51
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JJIJ
Johnson & Johnson Innovation - JJDC
New Jersey
+$63.9M
2
ASP
Adams Street Partners
Illinois
+$61M
3
O
OrbiMed
New York
+$56.2M
4
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
+$54.3M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$52.9M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
JJIJ
1
Johnson & Johnson Innovation - JJDC
New Jersey
$64.1M +$63.9M +3,670,516 New
O
2
OrbiMed
New York
$56.3M +$56.2M +3,224,770 New
ASP
3
Adams Street Partners
Illinois
$55.1M +$61M +3,502,425 New
Canada Pension Plan Investment Board
4
Canada Pension Plan Investment Board
Ontario, Canada
$54.5M +$54.3M +3,116,966 New
Fidelity Investments
5
Fidelity Investments
Massachusetts
$53.1M +$52.9M +3,038,998 New
TGHSA
6
TPG Group Holdings (SBS) Advisors
Texas
$44.6M +$44.4M +2,551,794 New
PA
7
Perceptive Advisors
New York
$36M +$38.9M +2,235,983 New
DM
8
Deerfield Management
New York
$22M +$21.9M +1,257,000 New
RSCM
9
Rock Springs Capital Management
Maryland
$16.4M +$16.3M +937,041 New
Morgan Stanley
10
Morgan Stanley
New York
$11.7M +$11.7M +671,418 New
BlackRock
11
BlackRock
New York
$7.92M +$7.89M +453,191 New
CCP
12
Clough Capital Partners
Massachusetts
$7.04M +$7.02M +402,800 New
Citadel Advisors
13
Citadel Advisors
Florida
$5.68M +$5.66M +325,001 New
Federated Hermes
14
Federated Hermes
Pennsylvania
$5.59M +$5.57M +320,000 New
FCM
15
Farallon Capital Management
California
$4.37M +$4.35M +250,000 New
Millennium Management
16
Millennium Management
New York
$3.68M +$3.67M +210,501 New
Victory Capital Management
17
Victory Capital Management
Texas
$3.21M +$3.2M +183,725 New
UBS AM
18
UBS AM
Illinois
$3.11M +$3.1M +178,155 New
Janus Henderson Group
19
Janus Henderson Group
United Kingdom
$3.11M +$3.1M +177,845 New
Invesco
20
Invesco
Georgia
$2.97M +$2.96M +170,000 New
APM
21
Avidity Partners Management
Texas
$2.88M +$2.87M +164,554 New
HM
22
HealthCor Management
New York
$2.62M +$2.61M +150,000 New
ACP
23
Acuta Capital Partners
California
$2.36M +$2.35M +135,000 New
LGM
24
Logos Global Management
California
$2.12M +$2.11M +121,128 New
WP
25
Woodline Partners
California
$2.1M +$2.09M +120,000 New
1
2 3

FUSN Hedge Fund Activity: Q2 2020 in Review

51 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Fusion Pharmaceuticals Inc. Common Shares (FUSN) for Q2 2020, worth a combined $483M.

Buyers outnumbered sellers: 51 funds opened new FUSN positions and 0 closed out — a net gain of 51 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Johnson & Johnson Innovation - JJDC, opening a new position worth an estimated $63.9M.

  • 51 institutional investors held Fusion Pharmaceuticals Inc. Common Shares (FUSN) as of Q2 2020, up from 0 in Q1 2020.
  • Funds reported $483M of Fusion Pharmaceuticals Inc. Common Shares stock for Q2 2020.
  • 51 funds opened new Fusion Pharmaceuticals Inc. Common Shares positions in Q2 2020 and 0 closed out, a net change of +51 holders.
  • The largest Fusion Pharmaceuticals Inc. Common Shares buyer in Q2 2020 was Johnson & Johnson Innovation - JJDC, an estimated $63.9M added.

Based on aggregated 13F filings for Q2 2020.